Advertisement
GKOS vs ISRG
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- Glaukos Corporation (GKOS) delivered quarterly revenue growth of 35.7% year-over-year (YoY), surpassing Intuitive Surgical (ISRG)'s 18.8%.
- ISRG maintains profitability with a trailing twelve months (TTM) price-to-earnings (PE) ratio of 59.16 and positive earnings per share (EPS) of $7.87, while GKOS reports negative EPS of -$3.28.
- GKOS stock has risen approximately 40% over the past year with recent monthly gains around 23%, compared to ISRG's relatively flat annual performance and recent monthly dip of about 3%.
- ISRG's market capitalization stands at $165 billion, dwarfing GKOS's $7.3 billion, reflecting greater scale and market presence.
- Both operate in medical devices, but GKOS focuses on glaucoma therapies while ISRG leads in robotic surgery systems.
- Upcoming earnings for both highlight potential catalysts: GKOS on April 29 and ISRG imminent, amid regulatory scrutiny for the latter.
Introduction
Both GKOS and ISRG represent innovative players in the medical technology sector, specializing in advanced devices for eye care and robotic surgery, respectively. This stock comparison analyzes their recent market performance, financial metrics, and growth trajectories in the current environment. Traders seeking exposure to healthcare innovation and investors evaluating relative performance in medtech will find value in understanding their contrasts in scale, profitability, and momentum. With both approaching earnings reports, the analysis highlights key factors influencing trader sentiment and positioning.
GKOS Overview and Recent Performance
Glaukos Corporation (GKOS) develops ophthalmic medical technologies and pharmaceuticals, primarily targeting glaucoma treatments through minimally invasive implants and sustained-release drug delivery systems. In recent market activity, the stock has shown strong upward momentum, trading around $124 with a 52-week range of $73 to $130. This follows robust fourth-quarter 2025 results with net sales up 36% to $143 million, driving TTM revenue to $507 million and quarterly growth of 35.7% YoY. Year-to-date gains stand at over 10%, with monthly advances near 23%, fueled by positive analyst updates and anticipation for Q1 2026 earnings on April 29. Sentiment has improved on sustained revenue expansion, though profitability challenges persist with negative EPS.
ISRG Overview and Recent Performance
Intuitive Surgical, Inc. (ISRG) dominates robotic-assisted minimally invasive surgery with its da Vinci systems, enabling precise procedures across specialties. Recently, shares trade near $466 in a 52-week range of $428 to $604, with year-to-date performance at about 18% but a monthly decline of roughly 3%. TTM revenue reached $10 billion, supported by 18.8% quarterly growth, alongside strong profitability (TTM EPS $7.87, PE 59). Performance reflects procedure volume increases but has been tempered by FDA scrutiny on stapler safety and analyst price target reductions ahead of Q1 2026 earnings. Market sentiment balances growth potential against regulatory headwinds in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available, each designed for stocks, ETFs, or crypto with diverse strategies like swing trading, trend following, and short-term signals. These bots feature impressive stats, including annualized returns from +15% to +168%, win rates of 54% to 88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 22 in top cases. Timeframes range from 5 minutes to 55 days, trading sets like semiconductors (e.g., NVDA, AMD), gold miners, and industrials. Only the most suitable for prevailing conditions earn a spot, offering varied risk profiles and historical performances to match trader preferences. Explore these tools to enhance your strategy in dynamic markets.
Head-to-Head Comparison
GKOS and ISRG both thrive in medical devices but diverge in focus: GKOS’ niche glaucoma innovations versus ISRG’s broad robotic platform. Growth drivers favor GKOS with faster revenue acceleration (35.7% vs. 18.8% quarterly), yet ISRG excels in profitability and scale (TTM revenue $10B vs. $507M). Recent momentum tilts to GKOS amid its post-earnings surge, while ISRG faces short-term pressure from regulatory issues. Risk factors include GKOS’ path to breakeven versus ISRG’s exposure to reimbursement changes and product recalls. Sector-wise, both benefit from aging demographics, but ISRG’s diversification offers stability over GKOS’ specialized positioning. Market sentiment leans positive for growth-oriented plays like GKOS in bullish healthcare rotations.
Tickeron AI Verdict
Tickeron’s AI currently favors Glaukos Corporation (GKOS) due to its superior recent trend consistency, explosive revenue growth, and relative outperformance in recent market activity. While ISRG provides stability through profitability and scale, GKOS’ catalysts position it probabilistically stronger for near-term upside amid healthcare momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GKOS is a Hold and ISRG is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 0 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s).
- GKOS’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 7 TA indicator(s) are bullish while ISRG’s TA Score has 5 bullish TA indicator(s).
- GKOS’s TA Score: 7 bullish, 2 bearish.
- ISRG’s TA Score: 5 bullish, 3 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а +5.17% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -1.48% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +23.45%. For the same industry, the average monthly price growth was +12.35%, and the average quarterly price growth was -13.81%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.06%. For the same industry, the average monthly price growth was +5.15%, and the average quarterly price growth was -12.66%.
Reported Earning Dates
GKOS is expected to report earnings on Aug 05, 2026.
ISRG is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Medical/Nursing Services (+23.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+3.06% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| GKOS | ISRG | GKOS / ISRG | |
| Capitalization | 7.68B | 144B | 5% |
| EBITDA | -144M | 3.95B | -4% |
| Gain YTD | 15.738 | -28.176 | -56% |
| P/E Ratio | N/A | 49.43 | - |
| Revenue | 551M | 10.6B | 5% |
| Total Cash | 277M | 4.52B | 6% |
| Total Debt | 103M | 87M | 118% |
GKOS | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 63 | 63 | |
SMR RATING 1..100 | 98 | 51 | |
PRICE GROWTH RATING 1..100 | 47 | 64 | |
P/E GROWTH RATING 1..100 | 60 | 84 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ISRG's Valuation (79) in the Medical Specialties industry is in the same range as GKOS (95). This means that ISRG’s stock grew similarly to GKOS’s over the last 12 months.
ISRG's Profit vs Risk Rating (63) in the Medical Specialties industry is in the same range as GKOS (63). This means that ISRG’s stock grew similarly to GKOS’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for GKOS (98). This means that ISRG’s stock grew somewhat faster than GKOS’s over the last 12 months.
GKOS's Price Growth Rating (47) in the Medical Specialties industry is in the same range as ISRG (64). This means that GKOS’s stock grew similarly to ISRG’s over the last 12 months.
GKOS's P/E Growth Rating (60) in the Medical Specialties industry is in the same range as ISRG (84). This means that GKOS’s stock grew similarly to ISRG’s over the last 12 months.
| GKOS | ISRG | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 62% | 4 days ago 57% |
| Stochastic ODDS (%) | 4 days ago 75% | 4 days ago 65% |
| Momentum ODDS (%) | 4 days ago 79% | 4 days ago 61% |
| MACD ODDS (%) | 4 days ago 81% | 4 days ago 50% |
| TrendWeek ODDS (%) | 4 days ago 78% | 4 days ago 63% |
| TrendMonth ODDS (%) | 4 days ago 70% | 4 days ago 69% |
| Advances ODDS (%) | 7 days ago 78% | 6 days ago 67% |
| Declines ODDS (%) | 5 days ago 68% | 20 days ago 59% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 79% |
| Aroon ODDS (%) | N/A | 4 days ago 65% |
Advertisement